Sermorelin is a synthetic peptide corresponding to the 1–29 region of natural GHRH (growth hormone–releasing hormone). It is used in model systems to study the regulation of growth hormone secretion, pulsatility of the GH–IGF-1 axis, and related metabolic and regenerative processes.
Concentration (test)
Unspecified
Packaging
Glass vial with sterile closure (5 mg powder)
Storage
2–8 °C, protect from moisture and light
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
GHRH (1–29); Sermorelin acetate
In laboratory studies, Sermorelin has been linked to research in areas such as:
- regulation of the GH–IGF-1 axis and dynamics of GH pulses,
- pituitary response and down/up-regulation of GHRH receptors,
- changes in metabolism and body composition in models,
- regenerative and connective tissues (collagen, healing),
- sleep and circadian control of GH secretion.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is Sermorelin?
Sermorelin is a peptide consisting of the first 29 amino acids of native GHRH. This length of sequence retains biological activity when bound to the GHRH receptor in the anterior pituitary. In experimental models, it serves to study the physiology of growth hormone secretion, interactions with somatostatin, and feedback through IGF-1.
Thanks to targeted stimulation of pituitary somatotropes, it allows for the investigation of GH pulsatility, the impact on metabolic pathways and markers of tissue repair.
How does Sermorelin work?
By binding to the GHRH receptor (GPCR), it activates G s -adenylate cyclase, increases cAMP, and activates PKA/CREB. This leads to increased synthesis and secretion of growth hormone from the pituitary gland. The effect is modulated by endogenous somatostatin and circadian rhythms, so the timing of application in relation to the natural nocturnal GH pulses is also monitored.
After reconstitution of the lyophilized powder, parenteral administration (sc or im) is used within the protocol, providing reproducible exposure curves for biomarker assessment.
Researched effects and interesting facts
-
GH pulsatility: mapping of pulse amplitude and frequency, interactions with somatostatin.
-
IGF-1 and metabolism: monitoring markers of protein synthesis and energy metabolism.
-
Tissue regeneration: observation of collagen and healing markers in experimental models.
-
Sleep architecture: relationship with nocturnal GH pulses and NREM phase.
-
Synergies with GHRP: exploring combinations with ghrelin receptor stimulating peptides while preserving physiological pulsatility.
Dosage in studies
The information provided is derived solely from research studies and is not intended for real-world use outside of a laboratory setting.
-
Dose: Not specified (selected by titration according to GH/IGF-1 biomarkers and protocol goal).
-
Form: subcutaneously or intramuscularly after preparation of solution from lyophilized powder.
-
Frequency: Unspecified (depends on GH pulse monitoring and sampling times).
-
Duration: Unspecified (acute and longer protocols depending on study design).
Possible side effects (injectable form)
- local irritation, redness or tenderness at the injection site,
- transient hot flashes, dizziness or headache,
- rarely nausea; in sensitive individuals monitor comfort after application.
Resources
- Review papers on GHRH, GHRH receptors and cAMP/PKA/CREB signaling in somatotropes.
- Experimental studies evaluating the dynamics of GH pulses, IGF-1, and interactions with somatostatin.
- Publications on the use of GHRH (1–29) in models of metabolism and tissue regeneration.
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is a summary of existing scientific literature and is for educational purposes only.
Sale
